Tenax Therapeutics (TENX) Cash & Equivalents (2016 - 2017)
Historic Cash & Equivalents for Tenax Therapeutics (TENX) over the last 8 years, with Q3 2017 value amounting to $1.8 million.
- Tenax Therapeutics' Cash & Equivalents rose 14425.37% to $1.8 million in Q3 2017 from the same period last year, while for Sep 2017 it was $1.8 million, marking a year-over-year increase of 14425.37%. This contributed to the annual value of $10.0 million for FY2016, which is N/A changed from last year.
- Per Tenax Therapeutics' latest filing, its Cash & Equivalents stood at $1.8 million for Q3 2017, which was up 14425.37% from $2.2 million recorded in Q2 2017.
- Tenax Therapeutics' Cash & Equivalents' 5-year high stood at $58.3 million during Q2 2014, with a 5-year trough of $722152.0 in Q3 2016.
- Moreover, its 5-year median value for Cash & Equivalents was $2.7 million (2016), whereas its average is $8.2 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 734332.75% in 2014, then plummeted by 8640.88% in 2015.
- Tenax Therapeutics' Cash & Equivalents (Quarter) stood at $783528.0 in 2013, then surged by 7343.33% to $58.3 million in 2014, then tumbled by 93.72% to $3.7 million in 2015, then surged by 173.08% to $10.0 million in 2016, then plummeted by 82.35% to $1.8 million in 2017.
- Its Cash & Equivalents was $1.8 million in Q3 2017, compared to $2.2 million in Q2 2017 and $7.0 million in Q1 2017.